J 2023

Clinical presentation and pulmonary function tests in post-acute COVID-19 patients

GENZOR, Samuel, Petr JAKUBEC, Milan SOVA, Jan MIZERA, Pavol JOPPA et. al.

Basic information

Original name

Clinical presentation and pulmonary function tests in post-acute COVID-19 patients

Authors

GENZOR, Samuel (203 Czech Republic), Petr JAKUBEC (203 Czech Republic), Milan SOVA (203 Czech Republic, belonging to the institution), Jan MIZERA (203 Czech Republic), Pavol JOPPA (703 Slovakia), Radim BURGET (203 Czech Republic) and Pavol POBEHA (703 Slovakia)

Edition

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30203 Respiratory systems

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 0.900 in 2022

RIV identification code

RIV/00216224:14110/23:00130052

Organization unit

Faculty of Medicine

DOI

UT WoS

000863250600001

Keywords in English

COVID-19; post-acute phase; clinical presentation; pulmonary function tests

Tags

Tags

International impact, Reviewed
Změněno: 26/1/2024 10:18, Mgr. Tereza Miškechová

Abstract

V originále

Aims. The study analysed post-acute COVID-19 symptoms and the pulmonary function test (PFT) results in patients surviving the native strain of the virus. Methods. The study was prospective; the inclusion criteria were positive PCR test for SARS-CoV-2 and age 18-100. Exclusion criteria were active respiratory infection, known or suspicious pre-existing pulmonary disease, cardiac failure, recent or acute pulmonary embolism, anaemia, and neuromuscular diseases. The recruitment period was 1st March 2020 - 25th December 2020. The initial examination was performed 4-12 weeks after the disease onset. All subjects underwent physical examination, anamnesis, chest x-ray and PFT. Results. The study involved 785 subjects (345 male) mean age 53.8 (SD 14.6). The disease severity groups were: mild (G1), moderate (G2) and severe/critical (G3). Anosmia was present in the acute disease phase in 45.2% of G1 patients, but only in 4.5% of G3 patients. Dyspnoea occurred frequently in more severe groups (40%, 51.8% and 63.7% for G1, G2 and G3 respectively), while cough and fatigue showed no relationship to disease severity. Females were more likely to experience persistent symptoms. PFT results were significantly decreased in more severe groups compared to the mild COVID-19 patients, diffusing capacity was 86.3%, 79% and 68% of predicted values in G1, G2 and G3 respectively. Conclusion. Anosmia during the acute phase was associated with mild disease, persisting dyspnoea was more frequent after more severe COVID-19. Females tended to have persisting symptoms in post-acute phase more frequently. PFT results showed decrease with disease severity.